Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of monovalent and bivalent recombinant protein COVID-19 vaccines in adults
PACTR202106588702901Phase 3Unknown
- Sponsor
- Sanofi
- Start
- Jun 2021
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19), sponsored by Sanofi. Primary endpoints: Efficacy against symptomatic COVID-19 in SARS-CoV-2-naive participants and Safety and reactogenicity. Status: unknown.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202106588702901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202106588702901.